Skip to main content
. 2019 Jun 21;11(6):872. doi: 10.3390/cancers11060872

Figure 1.

Figure 1

Characterization of sdAb K2, a sdAb that specifically binds to human PD-L1. (A) Representative sensograms showing the affinity/kinetics of different concentrations of purified sdAb K2 or avelumab, interacting with immobilized recombinant human PD-L1 protein, as determined in surface plasmon resonance (SPR). (B) Representative flow cytometry histograms showing labeling of PD-L1NEG (grey) versus PD-L1POS (red) 293T cells with mAbs specific for PD-L1, ctrl sdAb (sdAb R3B23), sdAb K2, control mAb (isotype-matched) or avelumab.